OBJECTIVES: To estimate the cost of treating patients with haemophilia and inhibitors in Morocco. METHODS: A systematic literature research was performed to identify data on the epidemiology and cost of haemophilia. In order to collect information about the characteristics of patients, treatment options available and prescribed, and the use of health care resources, a structured questionnaire was developed and sent to Moroccan key opinion leaders in haemophilia. Data were collected from the completed questionnaires and validated in a consensus meeting. A decision analytic model was developed to estimate the average direct medical costs per patient per year from the Moroccan NHS perspective. A sensitivity analysis was conducted, also considering values from the literature about other countries. RESULTS: Information about the characteristics and the management of Moroccan patients with haemophilia and inhibitors is scarce in the literature. Parameters from international literature and also values reported by the experts show a wide range in key variables, like patients’ weight, number of bleeding episodes, distribution of mild/moderate or severe patients and number of severe episodes. Estimated annual total costs were on average 1,754,635MAD (€159,145) per patient. After completing the sensitivity analysis, it was estimated that the average cost per patient could vary from 438,658 DHM (€39,786) to 2,485,734 (€225,456).  CONCLUSIONS: It is challenging to complete a cost study in a country where there are limited sources of local medical information, and especially in a low prevalence disease such as haemophilia.  As experts see limited number of patients with inhibitors, there is a high level of uncertainty about the patients’ characteristics, their management and therefore the key variables that drive costs. Despite the wide range in the cost estimates, this type of cost studies contribute to the better understanding of the disease and provide useful information for decisions related to the allocation of resources.